<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03480932</url>
  </required_header>
  <id_info>
    <org_study_id>R01DA026727</org_study_id>
    <secondary_id>R01DA026727</secondary_id>
    <nct_id>NCT03480932</nct_id>
  </id_info>
  <brief_title>Role of Pegylated Interferon in Combination With DAAs to Cure Hepatitis C As Soon As Possible - Hepatitis C [ASAP-C]</brief_title>
  <official_title>Role of Pegylated Interferon in Combination With Direct Acting Antivirals (DAAs) to Cure Hepatitis C As Soon As Possible (ASAP) - Hepatitis C [ASAP-C]</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins Bloomberg School of Public Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>YR Gaitonde Centre for AIDS Research and Education</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins Bloomberg School of Public Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this pilot trial is to compare the efficacy, measured as sustained&#xD;
      virologic response (SVR) at least 12 weeks after completion of therapy, across three study&#xD;
      regimens/delivery modalities: Arm 1 - 4 weeks of sofosbuvir (SOF) + daclatasvir (DAC) +&#xD;
      pegylated interferon alfa-2a (PEG) delivered using directly observed therapy (DOT); Arm 2 -&#xD;
      12 weeks of SOF+DAC delivered using DOT; and Arm 3 - 12 weeks of SOF+DAC delivered as per&#xD;
      standard of care (monthly dispensation with no DOT). Secondary objectives are 1)To compare&#xD;
      the cost per SVR for each of the three study arms; 2) To compare adherence among persons&#xD;
      across the three study arms; 3) To evaluate the safety, tolerability and acceptability of&#xD;
      treatment in the three arms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a non-blinded randomized clinical trial with 150 participants randomized at a&#xD;
      1:1:1 allocation ratio to one of three treatment arms.&#xD;
&#xD;
      Arm 1: Sofosbuvir (400mg/daily) + Daclatasvir (60mg/daily) + Pegylated Interferon alfa-2a&#xD;
      (180µg/weekly) for 4 weeks with a field-based DOT approach&#xD;
&#xD;
      Arm 2: Sofosbuvir (400mg/daily) + Daclatasvir (60mg/daily) for 12 weeks with a field-based&#xD;
      DOT approach&#xD;
&#xD;
      Arm 3: Sofosbuvir (400mg/daily) + Daclatasvir (60mg/daily) for 12 weeks with standard of care&#xD;
      dispensation (4 monthly doses)&#xD;
&#xD;
      Pegylated-interferon alfa-2a (PEG) will be delivered subcutaneously once weekly. Sofosbuvir&#xD;
      (SOF) and Daclatasvir (DAC) will be taken orally once daily for the entire study period.&#xD;
&#xD;
      The study will take place at the YR Gaitonde Centre for AIDS Education (YRG) and Johns&#xD;
      Hopkins University (JHU) Collaborative Integrated Care Center (YRG-JHU ICC) located within&#xD;
      the premises of the Chattisgarh Institute of Medical Sciences (CIMS) in Bilaspur in the state&#xD;
      of Chattisgarh, India.&#xD;
&#xD;
      Participants will be recruited from the YRG-JHU ICC in Bilaspur, which currently has 514&#xD;
      registered HCV antibody positive clients. The Bilaspur ICC is in the Chattisgarh Institute&#xD;
      for Medical Sciences (CIMS).&#xD;
&#xD;
      The primary outcome will be sustained virologic response (SVR12). Secondary outcomes include&#xD;
      cost per SVR12, adherence, safety and tolerability.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2, 2018</start_date>
  <completion_date type="Actual">November 2, 2018</completion_date>
  <primary_completion_date type="Actual">November 2, 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SVR12</measure>
    <time_frame>12 weeks after treatment completion, 16 weeks for SOF+DAC+PEG and 24 weeks for SOF+DAC</time_frame>
    <description>Percentage of participants achieving sustained virologic response 12 weeks quantification) after treatment is completed (SVR12) as assessed by HCV RNA less than the lower limit of quantification measured 12 weeks after treatment completion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>16 weeks for SOF+DAC+PEG and 24 weeks for SOF+DAC</time_frame>
    <description>Number of participants with treatment-related serious adverse events by laboratory tests and physician examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication Adherence</measure>
    <time_frame>4 weeks for SOF+DAC+PEG and 12 weeks for SOF+DAC</time_frame>
    <description>Adherence to medication regimen defined using a combination of the biometric data for Arms 1 and 2 and self-report and pill counts for Arm 3. Percentage reporting at least 90% adherence</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>SOF+DAC+PEG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sofosbuvir (400mg/daily) + Daclatasvir (60mg/daily) + Pegylated Interferon alfa-2a (180µg/weekly) for 4 weeks with a field-based DOT approach</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOF+DAC, DOT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sofosbuvir (400mg/daily) + Daclatasvir (60mg/daily) for 12 weeks with a field-based DOT approach</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOF+DAC, standard</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sofosbuvir (400mg/daily) + Daclatasvir (60mg/daily) for 12 weeks with standard of care dispensation (4 monthly doses)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir</intervention_name>
    <description>Direct acting antiviral agent used for the treatment of hepatitis C</description>
    <arm_group_label>SOF+DAC+PEG</arm_group_label>
    <arm_group_label>SOF+DAC, DOT</arm_group_label>
    <arm_group_label>SOF+DAC, standard</arm_group_label>
    <other_name>Sovaldi</other_name>
    <other_name>Hepcvir</other_name>
    <other_name>MyHep</other_name>
    <other_name>Hepcinat</other_name>
    <other_name>Resof</other_name>
    <other_name>SoviHep</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daclatasvir</intervention_name>
    <description>Direct acting antiviral agent used for the treatment of hepatitis C</description>
    <arm_group_label>SOF+DAC+PEG</arm_group_label>
    <arm_group_label>SOF+DAC, DOT</arm_group_label>
    <arm_group_label>SOF+DAC, standard</arm_group_label>
    <other_name>Daklinza</other_name>
    <other_name>Natdac</other_name>
    <other_name>Daclahep</other_name>
    <other_name>Dacihep</other_name>
    <other_name>Hepdac</other_name>
    <other_name>Mydekla</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated Interferon alfa-2a</intervention_name>
    <description>Antiviral agent used for the treatment of hepatitis C</description>
    <arm_group_label>SOF+DAC+PEG</arm_group_label>
    <other_name>Pegasys</other_name>
    <other_name>Taspiance</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Willing and able to provide written informed consent&#xD;
&#xD;
          2. Age ≥ 18 years&#xD;
&#xD;
          3. Documented evidence of chronic HCV infection (HCV RNA positive)&#xD;
&#xD;
          4. Participant is a resident of Bilaspur and can provide locator information that can be&#xD;
             verified by one of the study staff&#xD;
&#xD;
          5. If participant is co-infected with HIV, he/she must have a cluster of differentiation&#xD;
             4 (CD4) &gt; 350 cells/mm3 and be either: 1) antiretroviral therapy (ART) naïve or 2) on&#xD;
             ART be on a tenofovir-containing regimen. If a subject's CD4 drops below 350 cells/μl&#xD;
             (current threshold for HIV treatment in India), he/she will be able to initiate ART&#xD;
             but we will ensure that the subject starts on a tenofovir-containing regimen, which is&#xD;
             currently the standard for persons newly initiating ART in India.&#xD;
&#xD;
          6. Subjects must have the following laboratory parameters at screening:&#xD;
&#xD;
               1. alanine aminotransferase (ALT) ≤ 10 x the upper limit of normal (ULN)&#xD;
&#xD;
               2. aspartate aminotransferase (AST) ≤ 10 x ULN&#xD;
&#xD;
               3. Hemoglobin ≥ 10 g/dl for male and 9 g/dl for female subjects&#xD;
&#xD;
               4. International normalized ratio (INR) ≤ 1.5 x ULN unless subject has known&#xD;
                  hemophilia or is stable on an anticoagulant regimen affecting INR&#xD;
&#xD;
               5. Albumin ≥ 3 g/dl&#xD;
&#xD;
               6. Direct bilirubin ≤ 1.5 x ULN&#xD;
&#xD;
               7. Creatinine clearance ≥ 30 ml/min as calculated by the Cockcroft-Gault Equation&#xD;
&#xD;
               8. Alpha fetoprotein &lt; 50 ng/ml&#xD;
&#xD;
               9. Absolute neutrophil count (ANC) ≥ 1,500/μL&#xD;
&#xD;
              10. Platelets ≥ 90,000/μL&#xD;
&#xD;
              11. Thyroid stimulating hormone (TSH) ≤ ULN&#xD;
&#xD;
              12. FIB-4 &lt;3.25. FIB-4 is a non-invasive Marker of Hepatic Fibrosis: Fibrosis-4&#xD;
                  (FIB-4) which is calculated as the ratio of age in years and aminotransferase to&#xD;
                  platelet count. It is a non-invasive hepatic fibrosis index score combining&#xD;
                  standard biochemical values, platelets, alanine aminotransferase (ALT), AST and&#xD;
                  age that is calculated using formula: FIB-4 = (Age [years] x AST [U/L]) /&#xD;
                  (platelets [10^9/L] x (square root of ALT [U/L])). A FIB-4 index of &lt; 1.45&#xD;
                  indicated no or moderate fibrosis and an index of &gt; 3.25 indicated extensive&#xD;
                  fibrosis/cirrhosis.) Participants with a FIB-4 &gt;3.25 will be referred to the&#xD;
                  medical gastroenterology department for further assessment for cirrhosis. If&#xD;
                  cirrhosis is ruled out by medical gastroenterology, participants can be&#xD;
                  rescreened for the study.&#xD;
&#xD;
          7. A female subject is eligible to enroll in the study if it is confirmed that she is:&#xD;
&#xD;
               1. Not pregnant or nursing&#xD;
&#xD;
               2. Not of childbearing potential (i.e., women who have had a hysterectomy, have both&#xD;
                  ovaries removed or medically documented ovarian failure, or are postmenopausal&#xD;
                  women &gt; 50 years of age with cessation (for ≥12 months) of previously occurring&#xD;
                  menses)&#xD;
&#xD;
               3. Of childbearing potential (i.e., women who have not had a hysterectomy, both&#xD;
                  ovaries removed or medically documented ovarian failure). [NOTE: Women ≤50 years&#xD;
                  of age with amenorrhea will be considered to be of childbearing potential.] These&#xD;
                  women must have a negative urine pregnancy test at screening and a negative urine&#xD;
                  pregnancy test on the Baseline /Day 1 visit prior to randomization and agree to&#xD;
                  one of the following modes of contraception for the duration of treatment and 12&#xD;
                  weeks thereafter.&#xD;
&#xD;
                    -  Complete abstinence from intercourse. Periodic abstinence (e.g., calendar,&#xD;
                       ovulation, sumptothermal, post-ovulation methods) is NOT permitted.&#xD;
&#xD;
             or&#xD;
&#xD;
             i. Consistent and correct use of 1 of the following methods of birth control listed&#xD;
             below in addition to a male partner who correctly uses a condom from 3 weeks prior to&#xD;
             Baseline/Day 1 until the end of treatment. Women of childbearing potential must not&#xD;
             rely on hormone-containing contraceptives as a form of birth control during the study.&#xD;
             Female subjects using a hormone containing contraceptive prior to screening may&#xD;
             continue their contraceptive regimen in addition to the study specified methods of&#xD;
             birth control.&#xD;
&#xD;
               -  intrauterine device (IUD) with a documented failure rate of less than 1% per year&#xD;
&#xD;
               -  female barrier method: cervical cap or diaphragm with spermicidal agent&#xD;
&#xD;
               -  tubal sterilization&#xD;
&#xD;
               -  vasectomy in male partner&#xD;
&#xD;
          8. Subjects must be of generally good health as determined by the investigator.&#xD;
&#xD;
          9. Subjects must be able to comply with the dosing instructions for study drug&#xD;
             administration and be willing to complete the study schedule of assessments.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or nursing female&#xD;
&#xD;
          2. Current or prior history of clinical hepatic decompensation (e.g., ascites,&#xD;
             encephalopathy or variceal hemorrhage, model for end-stage liver disease (MELD)&lt;12)&#xD;
&#xD;
          3. Prior treatment for hepatitis C virus infection&#xD;
&#xD;
          4. Infection with hepatitis B virus (HBsAg positive)&#xD;
&#xD;
          5. Chronic use of systematically administered immunosuppressive agents (e.g., prednisone&#xD;
             equivalent &gt;10 mg/day)&#xD;
&#xD;
          6. Use of any prohibited concomitant medications within 28 days of the Baseline/Day 1&#xD;
             visit.&#xD;
&#xD;
          7. Contraindications to PEG&#xD;
&#xD;
          8. Known hypersensitivity to the metabolites or formulation excipients of PEG (for Arm 1&#xD;
             subjects)&#xD;
&#xD;
          9. Active significant psychiatric condition(s) including severe depression, severe&#xD;
             bipolar disorder and schizophrenia. Other psychiatric disorders are permitted if the&#xD;
             condition is well controlled with a stable treatment regimen for ≥ 1 year from&#xD;
             screening, or inactive for ≥ 1 year from screening.&#xD;
&#xD;
         10. Presence of autoimmune disorders (e.g., systemic lupus erythematosus, rheumatoid&#xD;
             arthritis, sarcoidosis, psoriasis of greater than mild severity)&#xD;
&#xD;
         11. History of clinical significant retinal disease&#xD;
&#xD;
         12. Clinical evidence of cirrhosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shruti Mehta, PhD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins Bloomberg School of Public Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>YR Gaitonde Centre for AIDS Education and Johns Hopkins University Collaborative Integrated Care Center (YRG-JHU ICC)</name>
      <address>
        <city>Bilaspur</city>
        <state>Chhattisgarh</state>
        <zip>495009</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 29, 2018</study_first_submitted>
  <study_first_submitted_qc>March 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2018</study_first_posted>
  <results_first_submitted>March 22, 2021</results_first_submitted>
  <results_first_submitted_qc>April 26, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 18, 2021</results_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>directly observed therapy</keyword>
  <keyword>sofosbuvir</keyword>
  <keyword>daclatasvir</keyword>
  <keyword>pegylated interferon</keyword>
  <keyword>resource-limited setting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon alpha-2</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Sofosbuvir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 25, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/32/NCT03480932/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>SOF+DAC+PEG</title>
          <description>Sofosbuvir (400mg/daily) + Daclatasvir (60mg/daily) + Pegylated Interferon alfa-2a (180µg/weekly) for 4 weeks with a field-based DOT approach&#xD;
Sofosbuvir: Direct acting antiviral agent used for the treatment of hepatitis C&#xD;
Daclatasvir: Direct acting antiviral agent used for the treatment of hepatitis C&#xD;
Pegylated Interferon alfa-2a: Antiviral agent used for the treatment of hepatitis C</description>
        </group>
        <group group_id="P2">
          <title>SOF+DAC, DOT</title>
          <description>Sofosbuvir (400mg/daily) + Daclatasvir (60mg/daily) for 12 weeks with a field-based DOT approach&#xD;
Sofosbuvir: Direct acting antiviral agent used for the treatment of hepatitis C&#xD;
Daclatasvir: Direct acting antiviral agent used for the treatment of hepatitis C</description>
        </group>
        <group group_id="P3">
          <title>SOF+DAC, Standard</title>
          <description>Sofosbuvir (400mg/daily) + Daclatasvir (60mg/daily) for 12 weeks with standard of care dispensation (4 monthly doses)&#xD;
Sofosbuvir: Direct acting antiviral agent used for the treatment of hepatitis C&#xD;
Daclatasvir: Direct acting antiviral agent used for the treatment of hepatitis C</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Incarcerated</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>SOF+DAC+PEG</title>
          <description>Sofosbuvir (400mg/daily) + Daclatasvir (60mg/daily) + Pegylated Interferon alfa-2a (180µg/weekly) for 4 weeks with a field-based DOT approach&#xD;
Sofosbuvir: Direct acting antiviral agent used for the treatment of hepatitis C&#xD;
Daclatasvir: Direct acting antiviral agent used for the treatment of hepatitis C&#xD;
Pegylated Interferon alfa-2a: Antiviral agent used for the treatment of hepatitis C</description>
        </group>
        <group group_id="B2">
          <title>SOF+DAC, DOT</title>
          <description>Sofosbuvir (400mg/daily) + Daclatasvir (60mg/daily) for 12 weeks with a field-based DOT approach&#xD;
Sofosbuvir: Direct acting antiviral agent used for the treatment of hepatitis C&#xD;
Daclatasvir: Direct acting antiviral agent used for the treatment of hepatitis C</description>
        </group>
        <group group_id="B3">
          <title>SOF+DAC, Standard</title>
          <description>Sofosbuvir (400mg/daily) + Daclatasvir (60mg/daily) for 12 weeks with standard of care dispensation (4 monthly doses)&#xD;
Sofosbuvir: Direct acting antiviral agent used for the treatment of hepatitis C&#xD;
Daclatasvir: Direct acting antiviral agent used for the treatment of hepatitis C</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="50"/>
            <count group_id="B4" value="150"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25" lower_limit="21" upper_limit="31"/>
                    <measurement group_id="B2" value="26" lower_limit="22" upper_limit="31"/>
                    <measurement group_id="B3" value="25" lower_limit="21" upper_limit="30"/>
                    <measurement group_id="B4" value="25" lower_limit="22" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Indian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Educational attainment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Primary school</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Secondary school</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>At least high school</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Employment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Monthly wages</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Weekly wages</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Daily wages</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="75"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unemployment</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Marital status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Never married</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="93"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Currently married</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Separated</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Living with partner</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Injection drug use frequency in prior month</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Once a week to less than twice a week</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="63"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Twice a week to six times a week</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Daily</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Non-injection drug use in prior month</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alcohol use</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No/mild use</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="138"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Harmful/hazardous use</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Alcohol dependence</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Depressive symptoms</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="96"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderately severe to severe</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Quality of life</title>
          <description>Quality of life evaluated using the Euro-Quality of life - 5 Dimensions (EQ5D) scale. The EQ-5D-5L is composed of - the EQ-5D-5L descriptive system and the EQ Visual Analogue scale (EQ VAS). The descriptive system comprises 5 dimensions (mobility, self care, usual activities, pain/discomfort, anxiety/depression). The EQ VAS corresponds to a 20 cm vertical, visual analogue scale raging from 'the best health you can imagine' to 'the worst health you can imagine' with values from 100 to 0. This outcome reported here is based on the EQ VAS which ranges from 0 to 100</description>
          <units>Self-rated health scale (0-100))</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90" lower_limit="80" upper_limit="100"/>
                    <measurement group_id="B2" value="78" lower_limit="50" upper_limit="95"/>
                    <measurement group_id="B3" value="80" lower_limit="60" upper_limit="96"/>
                    <measurement group_id="B4" value="80" lower_limit="60" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HIV-infected</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Median HCV RNA</title>
          <units>log 10 copies/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.4" lower_limit="4.1" upper_limit="6.3"/>
                    <measurement group_id="B2" value="5.6" lower_limit="4.3" upper_limit="6.2"/>
                    <measurement group_id="B3" value="5.7" lower_limit="5.1" upper_limit="6.5"/>
                    <measurement group_id="B4" value="5.6" lower_limit="4.4" upper_limit="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Median calculated fibrosis score (FIB-4)</title>
          <description>Fibrosis-4 (FIB-4) is a non-invasive Marker of Hepatic Fibrosis: Fibrosis-4 (FIB-4). Fibrosis-4 is the ratio of age in years and aminotransferase to platelet count. It is a non-invasive hepatic fibrosis index score combining standard biochemical values, platelets, alanine aminotransferase (ALT), AST and age that is calculated using formula: FIB-4 = (Age [years] x AST [U/L]) / (platelets [10^9/L] x (square root of ALT [U/L])). A FIB-4 index of &lt; 1.45 indicated no or moderate fibrosis and an index of &gt; 3.25 indicated extensive fibrosis/cirrhosis.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.69" lower_limit="0.51" upper_limit="0.88"/>
                    <measurement group_id="B2" value="0.68" lower_limit="0.47" upper_limit="1.12"/>
                    <measurement group_id="B3" value="0.73" lower_limit="0.54" upper_limit="1.14"/>
                    <measurement group_id="B4" value="0.68" lower_limit="0.49" upper_limit="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>SVR12</title>
        <description>Percentage of participants achieving sustained virologic response 12 weeks quantification) after treatment is completed (SVR12) as assessed by HCV RNA less than the lower limit of quantification measured 12 weeks after treatment completion</description>
        <time_frame>12 weeks after treatment completion, 16 weeks for SOF+DAC+PEG and 24 weeks for SOF+DAC</time_frame>
        <population>Intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>SOF+DAC+PEG</title>
            <description>Sofosbuvir (400mg/daily) + Daclatasvir (60mg/daily) + Pegylated Interferon alfa-2a (180µg/weekly) for 4 weeks with a field-based DOT approach&#xD;
Sofosbuvir: Direct acting antiviral agent used for the treatment of hepatitis C&#xD;
Daclatasvir: Direct acting antiviral agent used for the treatment of hepatitis C&#xD;
Pegylated Interferon alfa-2a: Antiviral agent used for the treatment of hepatitis C</description>
          </group>
          <group group_id="O2">
            <title>SOF+DAC, DOT</title>
            <description>Sofosbuvir (400mg/daily) + Daclatasvir (60mg/daily) for 12 weeks with a field-based DOT approach&#xD;
Sofosbuvir: Direct acting antiviral agent used for the treatment of hepatitis C&#xD;
Daclatasvir: Direct acting antiviral agent used for the treatment of hepatitis C</description>
          </group>
          <group group_id="O3">
            <title>SOF+DAC, Standard</title>
            <description>Sofosbuvir (400mg/daily) + Daclatasvir (60mg/daily) for 12 weeks with standard of care dispensation (4 monthly doses)&#xD;
Sofosbuvir: Direct acting antiviral agent used for the treatment of hepatitis C&#xD;
Daclatasvir: Direct acting antiviral agent used for the treatment of hepatitis C</description>
          </group>
        </group_list>
        <measure>
          <title>SVR12</title>
          <description>Percentage of participants achieving sustained virologic response 12 weeks quantification) after treatment is completed (SVR12) as assessed by HCV RNA less than the lower limit of quantification measured 12 weeks after treatment completion</description>
          <population>Intention to treat</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serious Adverse Events</title>
        <description>Number of participants with treatment-related serious adverse events by laboratory tests and physician examination</description>
        <time_frame>16 weeks for SOF+DAC+PEG and 24 weeks for SOF+DAC</time_frame>
        <population>Intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>SOF+DAC+PEG</title>
            <description>Sofosbuvir (400mg/daily) + Daclatasvir (60mg/daily) + Pegylated Interferon alfa-2a (180µg/weekly) for 4 weeks with a field-based DOT approach&#xD;
Sofosbuvir: Direct acting antiviral agent used for the treatment of hepatitis C&#xD;
Daclatasvir: Direct acting antiviral agent used for the treatment of hepatitis C&#xD;
Pegylated Interferon alfa-2a: Antiviral agent used for the treatment of hepatitis C</description>
          </group>
          <group group_id="O2">
            <title>SOF+DAC, DOT</title>
            <description>Sofosbuvir (400mg/daily) + Daclatasvir (60mg/daily) for 12 weeks with a field-based DOT approach&#xD;
Sofosbuvir: Direct acting antiviral agent used for the treatment of hepatitis C&#xD;
Daclatasvir: Direct acting antiviral agent used for the treatment of hepatitis C</description>
          </group>
          <group group_id="O3">
            <title>SOF+DAC, Standard</title>
            <description>Sofosbuvir (400mg/daily) + Daclatasvir (60mg/daily) for 12 weeks with standard of care dispensation (4 monthly doses)&#xD;
Sofosbuvir: Direct acting antiviral agent used for the treatment of hepatitis C&#xD;
Daclatasvir: Direct acting antiviral agent used for the treatment of hepatitis C</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Adverse Events</title>
          <description>Number of participants with treatment-related serious adverse events by laboratory tests and physician examination</description>
          <population>Intention to treat</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Medication Adherence</title>
        <description>Adherence to medication regimen defined using a combination of the biometric data for Arms 1 and 2 and self-report and pill counts for Arm 3. Percentage reporting at least 90% adherence</description>
        <time_frame>4 weeks for SOF+DAC+PEG and 12 weeks for SOF+DAC</time_frame>
        <population>Intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>SOF+DAC+PEG</title>
            <description>Sofosbuvir (400mg/daily) + Daclatasvir (60mg/daily) + Pegylated Interferon alfa-2a (180µg/weekly) for 4 weeks with a field-based DOT approach&#xD;
Sofosbuvir: Direct acting antiviral agent used for the treatment of hepatitis C&#xD;
Daclatasvir: Direct acting antiviral agent used for the treatment of hepatitis C&#xD;
Pegylated Interferon alfa-2a: Antiviral agent used for the treatment of hepatitis C</description>
          </group>
          <group group_id="O2">
            <title>SOF+DAC, DOT</title>
            <description>Sofosbuvir (400mg/daily) + Daclatasvir (60mg/daily) for 12 weeks with a field-based DOT approach&#xD;
Sofosbuvir: Direct acting antiviral agent used for the treatment of hepatitis C&#xD;
Daclatasvir: Direct acting antiviral agent used for the treatment of hepatitis C</description>
          </group>
          <group group_id="O3">
            <title>SOF+DAC, Standard</title>
            <description>Sofosbuvir (400mg/daily) + Daclatasvir (60mg/daily) for 12 weeks with standard of care dispensation (4 monthly doses)&#xD;
Sofosbuvir: Direct acting antiviral agent used for the treatment of hepatitis C&#xD;
Daclatasvir: Direct acting antiviral agent used for the treatment of hepatitis C</description>
          </group>
        </group_list>
        <measure>
          <title>Medication Adherence</title>
          <description>Adherence to medication regimen defined using a combination of the biometric data for Arms 1 and 2 and self-report and pill counts for Arm 3. Percentage reporting at least 90% adherence</description>
          <population>Intention to treat</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>16 weeks for Arm 1 and 24 weeks for ARms 2 and 3</time_frame>
      <group_list>
        <group group_id="E1">
          <title>SOF+DAC+PEG</title>
          <description>Sofosbuvir (400mg/daily) + Daclatasvir (60mg/daily) + Pegylated Interferon alfa-2a (180µg/weekly) for 4 weeks with a field-based DOT approach&#xD;
Sofosbuvir: Direct acting antiviral agent used for the treatment of hepatitis C&#xD;
Daclatasvir: Direct acting antiviral agent used for the treatment of hepatitis C&#xD;
Pegylated Interferon alfa-2a: Antiviral agent used for the treatment of hepatitis C</description>
        </group>
        <group group_id="E2">
          <title>SOF+DAC, DOT</title>
          <description>Sofosbuvir (400mg/daily) + Daclatasvir (60mg/daily) for 12 weeks with a field-based DOT approach&#xD;
Sofosbuvir: Direct acting antiviral agent used for the treatment of hepatitis C&#xD;
Daclatasvir: Direct acting antiviral agent used for the treatment of hepatitis C</description>
        </group>
        <group group_id="E3">
          <title>SOF+DAC, Standard</title>
          <description>Sofosbuvir (400mg/daily) + Daclatasvir (60mg/daily) for 12 weeks with standard of care dispensation (4 monthly doses)&#xD;
Sofosbuvir: Direct acting antiviral agent used for the treatment of hepatitis C&#xD;
Daclatasvir: Direct acting antiviral agent used for the treatment of hepatitis C</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Adherence measurements differ by arm (Arm 1 and 2 included daily observation of doses). Adherence assessment for Arm 3 based on participant completing a visit to pick up medication refill.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Shruti Mehta</name_or_title>
      <organization>Johns Hopkins Bloomberg School of Public Health</organization>
      <phone>4432873837</phone>
      <email>smehta@jhu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

